Alembic Pharma gets USFDA approval for depression treatment drug

·1-min read

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Sinequan capsules of Pfizer Inc. The drug is is used to treat mental/mood problems such as depression and anxiety.

The capsules have an estimated market size of $41 million for twelve months ending December 2020 according to IQVIA.

Alembic has a cumulative total of 141 ANDA approvals (124 final approvals and 17 tentative approvals) from USFDA.

Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world.

The drug maker reported 13.8% jump in consolidated net profit to Rs 259.20 crore on a 8.7% rise in net sales to Rs 1,314.33 crore in Q3 FY21 over Q3 FY20.

The Alembic Pharma scrip was up 0.29% to Rs 1006.65 on the BSE.



Source: Capitalmarket.com